Introduction {#S5}
============

The influence of postnatal somatic growth on neurodevelopmental outcomes in preterm infants has been well-described.^[@R1],\ [@R2],\ [@R3]^ Although much emphasis has been placed on achieving adequate weight gain in these infants, the importance of postnatal head growth in determining early childhood neurodevelopment has also been well-established.^[@R2],\ [@R4],\ [@R5]^ Efforts by neonatal care providers have decreased the incidence and severity of postnatal growth restriction; however, a decline in growth percentiles from birth to discharge still occurs commonly in those born prematurely. Standard deviation scores (z-scores) at birth for weight, length, and head circumference are similar and cluster around zero, suggesting in utero growth consistent with the population mean for any given gestational age.^[@R6]^ By hospital discharge, however, a decrease in z-score is routinely observed for weight, length, and head circumference.^[@R5],\ [@R6],\ [@R7]^ This decrease is more pronounced for weight and length than for head circumference z-score.^[@R5],\ [@R6],\ [@R7]^ This pattern, whereby postnatal head growth appears to be "spared" relative to weight, is neither well-understood nor well-studied. We refer to this phenomenon as postnatal head sparing (PHS). We postulated that this relative head sparing may be analogous in impact to *in utero* head sparing with respect to later neurodevelopmental outcome. Small for gestational age neonates born term and preterm with relative head sparing have neurodevelopmental outcomes that are significantly better than those babies whose head circumference percentiles are the same or lower than their birthweight percentiles.^[@R8],\ [@R9],\ [@R10]^ The objective of this study was to compare neurodevelopmental outcomes in postnatal growth-restricted extremely preterm infants with and without PHS.

Methods {#S6}
=======

This is an observational, retrospective study of prospectively collected data from the National Institute of Child Health and Human Development Neonatal Research Network's Generic Database (GDB) and Follow-Up studies. Infants 22 0/7 to 28 6/7 weeks gestation or with a birthweight of 401--1000 grams born 1/1/2009 to 12/31/2010 at participating NICHD Neonatal Research Network centers with postnatal growth restriction (PGR, defined below) and who underwent neurodevelopmental assessment at 18--22 months corrected age (CA) were included. Additional exclusion criteria included infants with missing growth data, congenital defects, hydrocephalus with shunt placement, birth head circumference (HC) \> 2 standard deviations above the mean for gestational age, and missing neurodevelopmental assessment at 18--22 months CA. Collection of comprehensive information on infants continued until "status," defined as hospital discharge or age 120 days, whichever came first.

Traditionally, growth percentiles at discharge have been used to characterize postnatal growth restriction in preterm infants. However, this approach has the potential to over-represent infants born small-for-gestational age (SGA, \<10%), who may very well experience a desired pattern of growth (ex: along the 5^th^ percentile) but are discharged \<10%. In order to better describe patterns of postnatal growth regardless of centiles at birth and discharge, standard deviation scores (z-scores) were used to define PGR and PHS. PGR and PHS were defined using the following formulas: $$\begin{array}{l}
{\mathbf{PGR}:\text{Weight}\,\text{z-score}\,\text{at}\,\text{status} - \text{Weight}\,\text{z-score}\,\text{at}\,\text{birth} < - 1} \\
{\mathbf{PHS}:\text{HC}\,\text{z-score}\,\text{at}\,\text{status} - \text{HC}\,\text{z-score}\,\text{at}\,\text{birth} \geq - 1} \\
\end{array}$$

The Fenton (2013) growth chart served as the reference for growth percentiles and corresponding z-scores, which were determined using the bulk calculator provided at <http://www.ucalgary.ca/fenton/2013chart>, used with permission.^[@R11]^ Data were collected for in-hospital morbidities, including rates of sepsis (culture-positive early or late septicemia/bacteremia treated for ≥ 5 days with antibiotics), necrotizing enterocolitis (NEC; modified Bell's stage IIa or greater), grade 3--4 intraventricular hemorrhage (IVH) and/or periventricular leukomalacia (PVL), bronchopulmonary dysplasia (BPD; defined as receiving supplemental O~2~ at 36 weeks PMA or discharge if discharged before 36 weeks), and postnatal corticosteroid use for BPD/chronic lung disease. Standardized neurodevelopmental examinations were performed at 18--22 months CA by certified examiners at each Neonatal Research Network center. Examiners undergo an annual re-certification process (described elsewhere) to ensure agreement with gold-standard examiners.^[@R12]^

The primary outcome for this study was Bayley III^[@R13]^ composite cognitive score. Additional measures of neurodevelopment comprised secondary outcomes, including Bayley III composite motor score, incidences of moderate-to-severe cerebral palsy, gross motor functional classification scale (GMFCS)^[@R14]^ level ≥ 2 and neurodevelopmental impairment (NDI), defined as having one or more of the following: Bayley III composite cognitive score \< 70, Bayley III composite motor score \< 70, GMFCS level ≥ 2, bilateral blindness, or hearing impairment. A second definition for NDI was also explored using a cognitive score cutoff of \< 85, rather than \< 70, based upon recent reports that higher cut points for the Bayley III composite cognitive scores may better identify infants with moderate-to-severe neurodevelopmental impairment.^[@R15],\ [@R16]^

Bivariate analyses were conducted to compare demographic characteristics, in-hospital morbidities, and outcomes between children with vs. without postnatal head sparing (PHS), using chi-square tests for categorical variables and t-tests for continuous variables. To determine whether PHS independently influenced neurodevelopmental outcomes, two sets of mixed effects regression models were conducted to compare outcomes for infants based on PHS after controlling for other factors and including center as a random effect. The first included PHS and demographic/birth characteristics only and the second added in-hospital morbidities and therapies to the model. The variables, chosen *a priori*, were selected if likely to influence growth and/or neurodevelopment. All analyses were performed using SAS version 9.4 with a p-value \< 0.05 indicating statistical significance. PROC MIXED was used for analyses of continuous outcomes (e.g., Bayley cognitive and motor composite scores) and PROC GLIMMIX for categorical outcomes (e.g., moderate/severe CP, GMFCS level ≥2, and NDI).

Results {#S7}
=======

Of 2238 infants born 1/1/2009 through 12/31/2010 and eligible for follow-up, 832 died (37%) and an additional 308 were excluded. The most common reasons for exclusion were missing growth or outcome data ([Figure 1](#F1){ref-type="fig"}). After exclusions, 658/1098 infants (59.9%) experienced PGR, survived to follow-up, and were subsequently included in the analyses. Of 658 infants with PGR, 301 (45.7%) met criteria for PHS.

Demographic and birth characteristics for infants with and without PHS are compared in [Table 1](#T1){ref-type="table"}. No significant differences were observed between groups with respect to postmenstrual age (PMA) at status, SGA at birth (defined as weight z-score at birth \< -1), gender, race, or ethnicity. The observed difference in mean GA at birth was statistically, but not clinically significant. At birth, mean weight and length z-scores were similar between groups with and without PHS, while mean HC z-score was greater in infants without PHS (0.09 ± 0.82 vs −0.36 ± 1.13, p\<0.001).

The distributions of weight and head circumference percentiles at birth and status for PHS and no PHS groups are displayed as density curves with histograms in [Figure 2](#F2){ref-type="fig"}. As expected for infants with PGR, the distribution curves for weight for both groups are shifted leftward from birth to status, which indicates a negative z-score change between birth and status. However, it was evident that a separation had occurred in the HC percentile distribution curves at the time of discharge (or 120 days), so that the curve for infants with PHS was relatively preserved while that for infants without PHS had shifted leftward.

[Table 2](#T2){ref-type="table"} displays bivariate analyses comparing in-hospital morbidities between groups. Infants with PHS had a lower incidence of NEC and sepsis, and similar rates of grade 3--4 IVH/PVL and BPD. Postnatal steroid treatment was similar between infants with and without PHS (19% vs 16%, p=0.365).

In unadjusted analyses, mean composite cognitive Bayley III scores at 18--22 months CA were not different between infants with and without PHS (90 vs 89) as shown in [Table 3](#T3){ref-type="table"}. However, infants with PHS had significantly higher motor scores and were less likely to have GMFCS ≥ 2 or NDI (using composite cognitive score \< 70) when compared with infants without PHS ([Table 3](#T3){ref-type="table"}). Results of both multivariable regression models are displayed in [Table 4](#T4){ref-type="table"}. When controlling for demographic and birth characteristics (Model 1), compared to infants without PHS those with PHS had higher Bayley III cognitive and motor scores and were significantly less likely to experience neurodevelopmental impairment when a composite cognitive score of \< 70 was used in the definition of NDI. In the second model, which controlled for in-hospital morbidities, the difference in motor score persisted, while the adjusted mean difference for cognitive score and odds of NDI were no longer significant. PHS did not impact the odds of GMFCS level ≥ 2 in either model.

Discussion {#S8}
==========

The association between postnatal growth failure and poorer neurodevelopmental outcomes in preterm infants has been well-established in several large cohort studies.^[@R1],\ [@R2],\ [@R3]^ Despite improvements in postnatal growth, due in part to more aggressive inpatient nutritional strategies, restricted growth between birth and discharge in those born prematurely remains a significant burden. Approximately 40% of nearly 26,000 VLBW infants in the California Perinatal Quality Collaborative database born 2005--2012 experienced a fall in weight z-score from birth to discharge of \> 1,^[@R17]^ while 60% of infants in our study experienced PGR using the same definition. In the face of restricted somatic growth, however, our findings from this large multicenter study suggest that a relative preservation of head growth between birth and discharge is associated with neurodevelopmental benefit, particularly in motor scores, in this at-risk population.

To our knowledge, this is the first study formally describing postnatal head-sparing and the first to assess outcomes in extremely preterm infants experiencing head-sparing growth during hospitalization. While the exact mechanisms behind PHS remain unclear, it is reasonable to consider several plausible factors that may contribute to preserved head growth. The influence of nutrient delivery on postnatal head growth should be considered, given that the developing brain of preterm infants relies on an adequate supply of macro- and micronutrients during a critical period of growth and development.^[@R18]^ Greater protein and caloric intake during the first 4 postnatal weeks has been shown to increase head circumference at both 28 days of life and 36 weeks postmenstrual age among infants \< 29 weeks gestation.^[@R19]^ Similarly, protein and fat intake during the first 10 postnatal weeks correlate positively with head growth in those born less than 27 weeks^[@R20]^, and very low birth weight infants experienced improved head growth following strategies implemented to increase caloric and protein intake.^[@R21]^ In extremely preterm infants, particularly those critically-ill, providing adequate nutrition to support growth is often limited by fluid restriction, inability to use the gut for feeding, or feeding tolerance, resulting in postnatal growth restriction similar to that experienced by infants in this study. However, detailed nutritional data are not available for our cohort, limiting the ability to assess the potential influence of protein and caloric intake on head growth in these infants.

In our population, infants without PHS were more likely to have NEC or sepsis. Evidence suggests that inflammation may also play a role in PHS. The accrual of lean body mass, considered a surrogate for organ growth, is altered by systemic inflammation. A sepsis model in rats results in decreased protein synthesis in skeletal muscle; the effect is mediated by TNF-α.^[@R22],\ [@R23]^ Increased TNF-α levels in breast milk from mothers of healthy one month old infants born at term are associated with lower infant lean body mass at one month of age.^[@R24]^ In preterm infants, improved anthropometric and bone growth occurs in the setting of lower levels of inflammatory mediators.^[@R25],\ [@R26]^ In addition to influencing growth, inflammation is known to be associated with poorer neurodevelopmental outcomes in extremely preterm infants. For example, elevated levels of inflammation-related proteins in the first two weeks of life in infants born \< 28 weeks increase the odds of microcephaly and lower Mental Developmental Index scores on the BSID-II at 2 years of age.^[@R27]^ Likewise, preterm infants with proven neonatal sepsis or necrotizing enterocolitis demonstrate structural changes in the brain and smaller head circumferences at 2 years of age.^[@R28]^ Moreover, adverse neurodevelopmental outcomes and poor head growth have been associated with neonatal infection in extremely low birthweight infants.^[@R29]^ In this observational cohort, we cannot determine whether inflammation contributed to the slower head growth seen in these infants or to poorer ND outcomes.

Although our results implicate the pattern of postnatal head growth as an independent predictor of ND outcomes, the study is not without limitations, some of which have already been mentioned. First, in the absence of a standard definition, we chose to define PHS using change in HC z-score between birth and discharge in a population of infants with restricted somatic growth. A recent study of outcomes in preterm infants growth-restricted at birth used z-scores to define restricted growth and classify infants as either symmetric or asymmetric, but did so with measurements obtained at a single time point (birth).^[@R8]^ Using a single measurement, such as z-score at birth *or* at discharge, prevents the ability to draw conclusions about the pattern of in-hospital growth. In addition, doing so would lead to exclusion and inclusion bias, whereby some infants with poor growth would be excluded (HC remains greater than a specified z-score or percentile) and others with 'normal' postnatal growth might be included (HC remains less than specified z-score or percentile). By using a change in z-score from birth to discharge to define both PGR and PHS, a pattern of head growth relative to somatic growth emerges, irrespective of any classification that could be applied at either birth or discharge.

Secondly, we defined PGR and PHS based on measurements taken at only two time points, which, while more informative than a single measurement, may not adequately describe the true pattern of postnatal growth. Our database (GDB) does not capture more frequent anthropometric measurements, limiting the ability to explore postnatal growth patterns in these infants. We would predict that, given the apparent association between head growth and both sepsis and NEC, nutrition as well as increases in weight and head circumference over the period of illness and recovery would be suboptimal. Other contributory factors might also become apparent if weekly measurements were available and analyzed.

Postnatal growth patterns, such as somatic growth relative to length and head growth relative to weight gain, and their relationship to long-term development require additional investigation. Defining more- or less-desirable patterns of growth in preterm infants requires more detailed growth data. Whether beneficial growth patterns are modifiable or achievable through targeted interventions remains in question.

Conclusion {#S9}
==========

Postnatal growth-restricted extremely preterm infants with postnatal head-sparing have improved ND outcome, specifically Bayley III motor scores, when compared to those without head sparing. Further investigation is needed to determine the impact of postnatal growth patterns on long-term health outcomes, whether patterns of growth are modifiable by clinicians, and if improved growth results in improvements in neurodevelopmental outcome in these fragile neonates when they are school-age and beyond.
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![Distribution Curves at Birth and Discharge\
Graphical depiction of weight and HC percentiles at birth and status in growth-restricted infants with (light gray, dashed line) and without (dark gray, solid line) PHS. The bars are constructed as histograms and the lines represent smoothed density curves. Note the expected leftward shift in weight percentiles between birth and status (A), and the preservation of head growth percentile in infants with PHS (B).](nihms812044f2){#F2}

###### 

Patient Demographic and Birth Characteristics

  Variable                                            PHS (n=301)    No PHS (n=357)   p-value
  --------------------------------------------------- -------------- ---------------- ---------
  GA at birth, wks                                    25.16 (1.10)   24.97 (1.09)     0.034
                                                                                      
  PMA at status[a](#TFN2){ref-type="table-fn"}, wks   39.40 (2.34)   39.12 (2.93)     0.175
                                                                                      
  SGA, n (%)                                          37 (12)        31 (9)           0.130
                                                                                      
  Male sex, n (%)                                     149 (50)       168 (47)         0.532
                                                                                      
  Race, n (%)                                                                         
   Black                                              141 (47)       134 (38)         0.055
   White                                              138 (46)       192 (54)         
   Other                                              19 (6)         27 (8)           
                                                                                      
  Hispanic Ethnicity, n (%)                           45 (16)        57 (17)          0.686
                                                                                      
  Maternal education less than high school, n (%)     45 (21)        56 (21)          0.984
                                                                                      
  Birth z-scores                                                                      
   Weight                                             0.11 (0.92)    0.10 (0.81)      0.818
   Length                                             0.05 (1.12)    0.00 (1.04)      0.594
   HC                                                 −0.36 (1.13)   0.09 (0.82)      \<0.001

Data displayed as mean (SD) unless otherwise noted.

Discharge or 120 days of age

###### 

Comparison of Morbidities Between Infants With and Without PHS

  Outcome                     PHS        No PHS     p-value
  --------------------------- ---------- ---------- ----------
  Sepsis, n (%)               79 (26)    141 (40)   \< 0.001
  NEC, n (%)                  24 (8)     62 (17)    \< 0.001
  IVH grade 3--4/PVL, n (%)   51 (17)    72 (20)    0.291
  BPD, n (%)                  144 (48)   194 (55)   0.091

###### 

Unadjusted Neurodevelopmental Outcomes

  Outcome                                PHS             No PHS          p-value
  -------------------------------------- --------------- --------------- ---------
  Bayley III cognitive composite score   90.78 (15.83)   89.14 (16.88)   0.205
                                                                         
  Bayley III motor composite score       90.75 (16.36)   86.77 (17.62)   0.004
                                                                         
  Moderate/severe CP, n (%)              20 (7)          35 (10)         0.148
                                                                         
  GMFCS level 2+, n (%)                  23 (8)          44 (12)         0.048
                                                                         
  NDI, n (%)                                                             
   *With cognitive score \< 70*          46 (16)         75 (22)         0.046
   *With cognitive score \< 85*          87 (29)         118 (34)        0.193

Data displayed as mean (SD) unless otherwise noted

###### 

Influence of PHS on Neurodevelopmental Outcomes in Regression Models

  Outcome                       Model 1: Demographics   Model 2: Demographics + Morbidities                        
  ----------------------------- ----------------------- ------------------------------------- -------------------- ---------
  Bayley III cognitive score    2.38 (0.54, 5.61)       0.018                                 2.47 (−0.01, 5.04)   0.06
  Bayley III motor score        5.1 (2.39, 7.81)        \<0.001                               4.65 (1.93, 7.38)    \<0.001
  GMFCS level 2+                0.62 (0.35, 1.10)       0.104                                 0.61 (0.33, 1.13)    0.117
  NDI (cognitive score \< 70)   0.60 (0.38, 0.94)       0.026                                 0.5 (0.39, 1.02)     0.058
  NDI (cognitive score \< 85)   0.73 (0.50, 1.08)       0.114                                 0.77 (0.51, 1.15)    0.199

Model 1 variables: GA at birth, sex, race/ethnicity, maternal education, PMA at status, SGA, HC z-score at birth

Model 2 variables: Model 1 + sepsis, NEC, IVH grade 3--4/PVL, postnatal steroids, BPD

Both models also controlled for clustering by center
